Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol

Ben Khaled, Najib; Seidensticker, Max; Ricke, Jens; Mayerle, Julia; Oehrle, Bettina; Roessler, Daniel; Teupser, Daniel; Ehmer, Ursula; Bitzer, Michael; Waldschmidt, Dirk; Fuchs, Martin; Reuken, Philipp A.; Lange, Christian M.; Wege, Henning; Kandulski, Arne; Dechene, Alexander; Venerito, Marino; Berres, Marie-Luise; Luedde, Tom; Kubisch, Ilja; Reiter, Florian P. und De Toni, Enrico N. (2022): Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. In: Future Oncology, Bd. 18, Nr. 12: S. 1423-1435

Abstract

The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than 80 countries. The efficacy and tolerability of this regimen suggest that the use of atezolizumab bevacizumab could be extended to the treatment of patients with intermediate-stage HCC in combination with transarterial chemoembolization (TACE). The authors describe the rationale and design of the DEMAND study. This investigator-initiated, multicenter, randomized phase 2 study is the first trial to evaluate the safety and efficacy of atezolizumab bevacizumab prior to or in combination with TACE in patients with intermediate-stage HCC. The primary end point is the 24-month survival rate;secondary end points include objective response rate, progression-free survival, safety and quality of life.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1479-6694
• Sprache: Englisch